Compare PRME & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | BBNX |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 493.1M |
| IPO Year | 2022 | N/A |
| Metric | PRME | BBNX |
|---|---|---|
| Price | $3.26 | $13.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $7.56 | ★ $23.80 |
| AVG Volume (30 Days) | ★ 2.8M | 908.6K |
| Earning Date | 05-08-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $7.06 | $34.90 |
| Revenue Next Year | $47.01 | $34.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $2.28 | $8.80 |
| 52 Week High | $6.94 | $32.71 |
| Indicator | PRME | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.54 | 59.85 |
| Support Level | $3.16 | $9.34 |
| Resistance Level | $3.68 | $15.53 |
| Average True Range (ATR) | 0.27 | 1.01 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 59.57 | 65.33 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.